Abstract
Preview
In Western countries, the number of persons affected by haemoglobinopathies, including sickle cell disease (SCD) and thalassaemia syndromes, is constantly increasing owing to migratory flows from the Middle East and Africa1. Blood transfusion remains a key treatment for many patients with haemoglobinopathies. However, selecting compatible units can be challenging, especially in the case of patients of Sub-Saharan (SSA) descent. In these populations, malaria has provided a major pressure favoring the selection of sickle cell trait and rare blood groups, conferring partial protection against Plasmodium infection. [ … ]
Downloads
- Abstract viewed - 282 times
- PDF downloaded - 68 times